文献速递湿疹皮炎与荨麻疹皮肤肿瘤

特应性皮炎患者口服免疫抑制剂与宫颈肿瘤风险

Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-10-10

该回顾性队列研究纳入1989年至2014年荷兰两家大学医学中心257例接受口服免疫抑制剂超过2个月成年女性特应性皮炎患者,其中189例有宫颈检查病理数据,中位治疗总时长407.0天(IQR 243.0-940.0),未发现治疗期间或之后发生宫颈癌,认为无需强化宫颈肿瘤筛查。

要点

  • 女性AD患者口服免疫抑制剂期间未观察到宫颈癌发生
  • 中位治疗总时长407.0天,73.5%患者有宫颈检查记录
  • 研究者认为无需对该人群实施强化宫颈肿瘤筛查

核心结论

  • 女性特应性皮炎患者使用口服免疫抑制剂期间或之后未发现宫颈癌。
  • 基于此队列,无需为此类患者制定强化宫颈肿瘤筛查方案。

研究设计与样本

  • 荷兰两家大学医学中心开展的回顾性队列研究。
  • 纳入1989年至2014年1月1日期间接受口服免疫抑制剂超过2个月的成年女性AD患者257例。
  • 口服免疫抑制剂包括环孢素A、硫唑嘌呤、甲氨蝶呤、吗替麦考酚酯、肠溶霉酚酸钠和缓释他克莫司。
  • 通过国家组织病理学登记系统筛查PAP3a、CIN I、CIN II、CIN III和宫颈癌记录。

主要发现

  • 257例患者中189例(73.5%)在国家组织病理学数据库中有宫颈检查结果。
  • 189例有宫颈检查结果患者的中位治疗总时长为407.0天(IQR 243.0-940.0)。
  • 患者组中未发现免疫抑制治疗期间或之后发生宫颈癌。

临床怎么用

  • 对于使用口服免疫抑制剂的女性AD患者,本研究未提示宫颈癌风险增加。
  • 当前证据不支持对此类患者常规实施强化宫颈肿瘤筛查。
  • 临床决策仍需结合个体风险评估和现有筛查指南。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral immunosuppressive drugs are frequently prescribed in young women with atopic dermatitis (AD). Immunocompromised patients may have a higher risk of developing high-risk HPV infections, cervical intra-epithelial neoplasia (CIN) and cervical carcinoma. Most literature on patients using oral immunosuppressive drugs is available in organ transplant patients. Literature on the risk of developing cervical carcinoma in AD patients treated with oral immunosuppressive drugs is lacking. At this moment, there is no clear guideline/consensus on this topic, but in daily practice, questions arise concerning whether this risk is increased and whether more intensive screening in women using immunosuppressive drugs should take place. OBJECTIVE: To investigate the occurrence of cervical carcinoma in women with AD treated with oral immunosuppressive drugs. METHODS: In this retrospective cohort study in two university medical centres in the Netherlands, all female adult AD patients receiving oral immunosuppressive drugs (cyclosporine A, azathioprine, methotrexate, mycophenolate mofetil, enteric-coated mycophenolate sodium and extended release tacrolimus) for more than 2 months between 1989 and 1 January 2014 were included. Patient files in the national histopathology register were screened for PAP3a, CIN I, CIN II, CIN III and cervical carcinoma. RESULTS: A total of 257 female AD patients with one or more treatment episodes from 1989 until 1 January 2014 were identified and included in this study. In 189 patients (73.5%), results of cervical examination were reported in the national histopathology database. Median total duration of treatment in these 189 women was 407.0 days (IQR 243.0-940.0). No cervical carcinoma during or following immunosuppressive therapy was found in our patient group. CONCLUSIONS: No intensified screening programme for cervical neoplasia seems necessary for women with AD using oral immunosuppressive drugs.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Garritsen FM, Verheijen RHM, Gerestein CG, et al. Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs? J Eur Acad Dermatol Venereol. 2017. PMID: 28925576. doi:10.1111/jdv.14593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。